Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
Quarterly results
Director departure
CC transcript
ALBIREO PHARMA, INC. (ALBO) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/08/2022 8-K Quarterly results
Docs: "Albireo Reports Q3 2022 Financial Results and Business Update"
08/15/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Albireo Reports Q3 Financial Results and Business Update"
08/05/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Albireo Pharma, Inc. Condensed Consolidated Balance Sheets September 30, December 31, 2020 2019 Assets Current assets: Cash and cash equivalents $ 278,691 $ 131,843 Prepaid expenses and other current assets 8,199 9,956 Total current assets 286,890 141,799 Property and equipment, net 551 597 Goodwill 17,260 17,260 Other assets 6,401 5,413 Total assets $ 311,102 $ 165,069 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 3,601 $ 4,785 Accrued expenses 16,817 13,486 Other current liabilities 810 653 Total current liabilities 21,228 18,924 Liability related to sale of future royalties 64,871 48,714 Note payable, net of discount 9,508 — Other long-term liabilities 3,735 4,270 Total liabilities 99,342 71,908 Stockholders’ Equity: Common stock, $0.01 par value per shar..."
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/02/2020 8-K Quarterly results
11/06/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
Docs: "Albireo Reports Second Quarter 2019 Financial Results"
05/09/2019 8-K Quarterly results
Docs: "Albireo Reports First Quarter 2019 Financial Results"
03/07/2019 8-K Quarterly results
11/13/2018 8-K Quarterly results
Docs: "Albireo Reports Third Quarter 2018 Financial Results"
08/07/2018 8-K Quarterly results
Docs: "Albireo Reports Second Quarter 2018 Financial Results"
03/15/2018 8-K Quarterly results
Docs: "Albireo Reports Fourth Quarter and Year-End 2017 Financial Results — Phase 3 PFIC trial of IBAT inhibitor A4250 planned to initiate in spring 2018 — — Elobixibat approved in Japan, becoming the first IBAT inhibitor approved in the world"
11/14/2017 8-K Quarterly results
Docs: "Albireo Reports Third Quarter 2017 Financial Results — Executing towards planned A4250 Phase 3 PFIC trial — — Decision on potential approval of elobixibat in Japan expected in the first half of 2018"
05/10/2017 8-K Form 8-K - Current report
03/14/2017 8-K Form 8-K - Current report
05/09/2016 8-K Quarterly results
Docs: "BIODEL REPORTS SECOND QUARTER FISCAL YEAR 2016 FINANCIAL RESULTS"
02/16/2016 8-K Quarterly results
Docs: "BIODEL REPORTS FIRST QUARTER FISCAL YEAR 2016 FINANCIAL RESULTS"
12/17/2015 8-K Quarterly results
Docs: "BIODEL REPORTS FOURTH QUARTER AND FISCAL YEAR 2015 FINANCIAL RESULTS Company Announces Plan to Explore Strategic Alternatives Conference Call and Audio Webcast to be Held Today, December 17, at 5:00 p.m. ET"
12/17/2014 8-K Quarterly results
Docs: "BIODEL REPORTS FOURTH QUARTER FISCAL YEAR 2014 FINANCIAL RESULTS Conference Call and Audio Webcast to be Held Today, December 17, at 5:00 p.m. ET"
12/18/2013 8-K Quarterly results
Docs: "BIODEL REPORTS FOURTH QUARTER FISCAL YEAR 2013 FINANCIAL RESULTS Conference Call and Audio Webcast Will be Held Today, December 18th, at 5:00 p.m. ET"
12/18/2012 8-K Form 8-K - Current report
02/08/2012 8-K Form 8-K - Current report
12/06/2011 8-K Form 8-K - Current report
08/04/2011 8-K Form 8-K - Current report
02/03/2011 8-K Form 8-K - Current report
12/09/2010 8-K Form 8-K - Current report
08/05/2010 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy